A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer

被引：0

作者：

Soliman, Hatem ^{[1
]}

Aldrich, Amy ^{[2
]}

Abdo, Neveen ^{[1
]}

Han, Hyo ^{[1
]}

Soyano, Aixa ^{[1
]}

Costa, Ricardo ^{[1
]}

Armaghani, Avan ^{[1
]}

Kiluk, John ^{[1
]}

Khakpour, Nazanin ^{[1
]}

Lee, Marie Catherine ^{[1
]}

Hoover, Susan ^{[1
]}

Laronga, Christine ^{[1
]}

Niell, Bethany ^{[3
]}

Mooney, Blaise ^{[3
]}

Weinfurtner, Robert Jared ^{[3
]}

Rosa, Marilin ^{[4
]}

Czerniecki, Brian ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Breast Oncol, Tampa, FL 33612 USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, Tampa, FL USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Anat Pathol, Tampa, FL USA

来源：

NPJ BREAST CANCER | 2025年 / 11卷 / 01期

关键词：

FREE CHEMOTHERAPY REGIMENS; CARDIAC SAFETY; TRASTUZUMAB; PERTUZUMAB; VACCINE; IMPACT;

D O I：

10.1038/s41523-025-00742-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Type 1 dendritic cell vaccines targeting HER2 (HER2-DC1) reinvigorates antitumor immunity which correlates with neoadjuvant therapy response. A pilot trial (clinicaltrials.gov,NCT03387553,1/2/2018) using HER2-DC1 pre-neoadjuvant therapy evaluated feasibility/safety and pathologic response rates/immunogenicity. Stage II-III ER-HER2+ breast cancer patients prescribed neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) were enrolled. HER2-DC1 (2x107 cells/vaccine) was given for 3 weeks prior to chemotherapy intranodal (IN) 1x/week (Arm A), IN 2x/week (Arm B), and 2x/week alternating intratumoral (IT) and IN (Arm C). HER2 ELISPOT counts (EHC) and immunofluorescence analysis of biopsies were performed. Six patients enrolled in Arms A and B, 18 patients in Arm C. Neoadjuvant HER2-DC1 demonstrated no unexpected safety signals. Pathologic complete response rates (pCR) across arms A, B, C were 42.8%, 66.6%, and 72.7%. Intranodal HER2-DC1 increased EHC, but IT + IN HER2-DC1 reduced EHC, possibly due to increased T cell tumor trafficking. Immunofluorescence showed increased T cell infiltration following IT + IN injections. Additional IT HER2-DC1 investigation is warranted.

引用

页数：9

共 18 条

[1] Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC) [J].

Adams, Sylvia ;

Goldstein, Lori J. ;

Sparano, Joseph A. ;

Demaria, Sandra ;

Badve, Sunil S. .

ONCOIMMUNOLOGY, 2015, 4 (09) :1-3

[2] Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine [J].

Basu, Amrita ;

Albert, Gabriella K. ;

Awshah, Sabrina ;

Datta, Jashodeep ;

Kodumudi, Krithika N. ;

Gallen, Corey ;

Beyer, Amber ;

Smalley, Keiran S. M. ;

Rodriguez, Paulo C. ;

Duckett, Derek R. ;

Forsyth, Peter A. ;

Soyano, Aixa ;

Koski, Gary K. ;

Costa, Ricardo Lima Barros ;

Han, Heather ;

Soliman, Hatem ;

Lee, Marie Catherine ;

Kalinski, Pawel ;

Czerniecki, Brian J. .

CANCER IMMUNOLOGY RESEARCH, 2022, 10 (01) :108-125

[3] Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies [J].

Cilibrasi, Chiara ;

Papanastasopoulos, Panagiotis ;

Samuels, Mark ;

Giamas, Georgios .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21) :23-45

[4] The development and use of the E75 (HER2 369-377) peptide vaccine [J].

Clifton, Guy T. ;

Peoples, George E. ;

Mittendorf, Elizabeth A. .

FUTURE ONCOLOGY, 2016, 12 (11) :1321-1329

[5] Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration [J].

Datta, Jashodeep ;

Rosemblit, Cinthia ;

Berk, Erik ;

Showalter, Lori ;

Namjoshi, Prachi ;

Mick, Rosemarie ;

Lee, Kathreen P. ;

Brod, Andrew M. ;

Yang, Rachel L. ;

Kelz, Rachel R. ;

Fitzpatrick, Elizabeth ;

Hoyt, Clifford ;

Feldman, Michael D. ;

Zhang, Paul J. ;

Xu, Shuwen ;

Koski, Gary K. ;

Czerniecki, Brian J. .

ONCOIMMUNOLOGY, 2015, 4 (10)

[6] Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer [J].

Han, Hyo S. ;

Aldrich, Amy L. ;

Garg, Saurabh K. ;

Weinfurtner, R. Jared ;

Nguyen, Jonathan V. ;

Mo, Qianxing ;

Whiting, Junmin ;

Childress, Jennifer ;

Soliman, Hatem ;

Costa, Ricardo ;

Armaghani, Avan ;

Soyano, Aixa ;

Kiluk, John ;

Hoover, Susan ;

Lee, Marie C. ;

Khakpour, Nazanin ;

Shenoi, Nithin ;

Jameel, Zena ;

Koski, Gary K. ;

Czerniecki, Brian J. .

JAMA ONCOLOGY, 2025, 11 (02) :119-127

[7]

Hardin M, 2016, ANN SURG ONCOL, V23, pS17

[8] Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland [J].

Jagiello-Gruszfeld, Agnieszka Irena ;

Rosinska, Magdalena ;

Meluch, Malgorzata ;

Pogoda, Katarzyna ;

Niwinska, Anna ;

Sienkiewicz, Renata ;

Grous, Aleksander ;

Winter, Pawel ;

Nowecki, Zbigniew I. .

CANCERS, 2022, 14 (05)

[9] Conventional type 1 dendritic cells (cDC1) as cancer therapeutics: challenges and opportunities [J].

Johnson, Phillip ;

Rosendahl, Nikita ;

Radford, Kristen J. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (04) :465-472

[10] Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial [J].

Kolberg-Liedtke, Cornelia ;

Feuerhake, Friedrich ;

Garke, Madlen ;

Christgen, Matthias ;

Kates, Ronald ;

Grischke, Eva Maria ;

Forstbauer, Helmut ;

Braun, Michael ;

Warm, Mathias ;

Hackmann, John ;

Uleer, Christoph ;

Aktas, Bahriye ;

Schumacher, Claudia ;

Kuemmel, Sherko ;

Wuerstlein, Rachel ;

Graeser, Monika ;

Nitz, Ulrike ;

Kreipe, Hans ;

Gluz, Oleg ;

Harbeck, Nadia .

BREAST CANCER RESEARCH, 2022, 24 (01)

← 1 2 →